Literature DB >> 24582292

A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females.

Andrea E Bonny1, Hannah L H Lange2, Lynette K Rogers3, Dave M Gothard4, Michael D Reed5.   

Abstract

OBJECTIVE: To explore the relationship between medroxyprogesterone acetate (MPA) pharmacokinetic (PK) parameter estimates and weight gain. STUDY
DESIGN: Prospective study of adolescents (N=40; age 12-21 years) initiating DMPA. PK parameters were calculated: maximum MPA concentration (Cmax, ng/mL), time to Cmax (Tmax, days) and elimination rate constant (ng/mL/day). Optimal PK cut points were determined for predicting body mass index (BMI) increase ≥10%.
RESULTS: Cmax <2.88 ng/mL and elimination rate constant <0.021 ng/mL/day were associated (p<.05) with BMI increase ≥10%. Elimination rate constant was most predictive of weight gain.
CONCLUSIONS: PK evaluation may help identify adolescents at risk of excessive DMPA-associated weight gain.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescence; Contraception; Depo Provera; Pharmacokinetics; Weight

Mesh:

Substances:

Year:  2014        PMID: 24582292      PMCID: PMC4019679          DOI: 10.1016/j.contraception.2014.01.017

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

1.  Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-ProveraR to women.

Authors:  S Jeppsson
Journal:  Contraception       Date:  1976-10       Impact factor: 3.375

2.  Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents.

Authors:  C M O'Dell; C M Forke; M M Polaneczky; S J Sondheimer; G B Slap
Journal:  Obstet Gynecol       Date:  1998-04       Impact factor: 7.661

3.  Weight change in adolescents who used hormonal contraception.

Authors:  W L Risser; L R Gefter; M S Barratt; J M Risser
Journal:  J Adolesc Health       Date:  1999-06       Impact factor: 5.012

4.  Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method.

Authors:  Andrea E Bonny; Julie Ziegler; Ray Harvey; Sara M Debanne; Michelle Secic; Barbara A Cromer
Journal:  Arch Pediatr Adolesc Med       Date:  2006-01

5.  Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.

Authors:  M Polaneczky; M Liblanc
Journal:  J Adolesc Health       Date:  1998-08       Impact factor: 5.012

6.  Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.

Authors:  A Ortiz; M Hirol; F Z Stanczyk; U Goebelsmann; D R Mishell
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

7.  Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval.

Authors:  Jennifer Smit; Julia Botha; Lynn McFadyen; Mags Beksinska
Journal:  Contraception       Date:  2004-01       Impact factor: 3.375

8.  Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate.

Authors:  Sharon A Mangan; Pamela G Larsen; Suzanne Hudson
Journal:  J Pediatr Adolesc Gynecol       Date:  2002-04       Impact factor: 1.814

9.  Blood levels of medroxyprogesterone acetate after multiple injections of depoprovera or cycloprovera.

Authors:  S Koetsawang; K Shrimanker; K Fotherby
Journal:  Contraception       Date:  1979-07       Impact factor: 3.375

  9 in total
  7 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  Serum adipocytokines and adipose weight gain: a pilot study in adolescent females initiating depot medroxyprogesterone acetate.

Authors:  Andrea E Bonny; Hannah L H Lange; Erinn M Hade; Bram Kaufman; Michael D Reed; Sam Mesiano
Journal:  Contraception       Date:  2015-06-10       Impact factor: 3.375

3.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

Review 4.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

5.  The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations.

Authors:  Roslyn M Ray; Michelle F Maritz; Chanel Avenant; Michele Tomasicchio; Sigcinile Dlamini; Zephne van der Spuy; Janet P Hapgood
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

6.  Changes in body weight and blood pressure among women using Depo-Provera injection in Northwest Ethiopia.

Authors:  Muluken Fekadie Zerihun; Tabarak Malik; Yohannes Mulu Ferede; Tesfahun Bekele; Yigizie Yeshaw
Journal:  BMC Res Notes       Date:  2019-08-15

Review 7.  Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review.

Authors:  P Silva; S Qadir; A Fernandes; L Bahamondes; J F Peipert
Journal:  Braz J Med Biol Res       Date:  2018-04-23       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.